D. James

发表

Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK.

M. Kaufmann, N. Woodford, D. Livermore, 2004, The Journal of antimicrobial chemotherapy.

Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis

R C George, D. Livermore, R. George, 2000, BMJ : British Medical Journal.

Are routine sensitivity test data suitable for the surveillance of resistance? Resistance rates amongst Escherichia coli from blood and CSF from 1991-1997, as assessed by routine and centralized testing.

D. Livermore, D. James, A. Johnson, 2000, The Journal of antimicrobial chemotherapy.

Regional variation in ampicillin and trimethoprim resistance in Escherichia coli in England from 1990 to 1997, in relation to antibacterial prescribing.

D. Livermore, D. Northcott, R. George, 2000, The Journal of antimicrobial chemotherapy.

Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline.

N. Woodford, D. Livermore, A. Kearns, 2015, The Journal of antimicrobial chemotherapy.

Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK.

D. Livermore, D. James, M. Warner, 2010, The Journal of antimicrobial chemotherapy.

Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method.

D. Livermore, D. James, S. Mushtaq, 2007, The Journal of antimicrobial chemotherapy.

Reliability of routine disc susceptibility testing by the British Society for Antimicrobial Chemotherapy (BSAC) method.

D. Livermore, D. James, A. Johnson, 2004, The Journal of antimicrobial chemotherapy.

Population structure and antibiotic resistance of Acinetobacter DNA group 2 and 13TU isolates from hospitals in the UK.

N. Woodford, D. Livermore, D. James, 2002, Journal of medical microbiology.

Trends in Fluoroquinolone (Ciprofloxacin) Resistance in Enterobacteriaceae from Bacteremias, England and Wales, 1990–1999

D. Livermore, R. George, D. James, 2002, Emerging infectious diseases.

Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).

N. Woodford, D. Livermore, D. James, 2002, The Journal of antimicrobial chemotherapy.

Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

D. Livermore, D. James, A. Johnson, 2000, The Journal of antimicrobial chemotherapy.

Increasing prevalence of methicillin resistance amongst Staphylococcus aureus blood culture isolates.

D. Livermore, D. James, A. Johnson, 1999, Journal of Antimicrobial Chemotherapy.

Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989–95

D. James, R. Marples, D James, 1997, The Lancet.

Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test.

D. Livermore, D. James, M. Warner, 2001, The Journal of antimicrobial chemotherapy.

Activity of ertapenem against Neisseria gonorrhoeae.

D. Livermore, K. Fenton, D. James, 2004, The Journal of antimicrobial chemotherapy.

Antibiotic susceptibility of streptococci and related genera causing endocarditis: analysis of UK reference laboratory referrals, January 1996 to March 2000

D. Livermore, R. George, D. James, 2001, BMJ : British Medical Journal.

Susceptibility of Gram-positive bacteria from ICU patients in UK hospitals to antimicrobial agents.

D. Livermore, D. James, A. Johnson, 2003, The Journal of hospital infection.

Continuing increase in invasive methicillin-resistant infection

D. James, Ap Johnson, A. Johnson, 1997, The Lancet.

Knowing the susceptibility profile of a P. aeruginosa isolate associated with an infection

D. James, R. Alma, V. Kosa, 2014 .

In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles.

A. Charlett, D. Livermore, D. James, 2003, International Journal of Antimicrobial Agents.

Genetic andPhysiological Studies of Bacteriophage T5 III. Patterns ofDeoxyribonucleic AcidSynthesis InducedbyMutantsofT5 andtheIdentification ofGenesInfluencing theAppearance ofPhage-Induced Dihydrofolate Reductase andDeoxyribonucleasel

D. James, H. E. Hendrickson, 1972 .

Susceptibility testing challenges with ceftaroline, MRSA and a 1 mg/L breakpoint.

N. Woodford, D. Livermore, D. James, 2015, The Journal of antimicrobial chemotherapy.

Etest® versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: results from PREMIUM, a European multicentre study

A. Oliver, M. Delmée, D. Livermore, 2017, The Journal of antimicrobial chemotherapy.

Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England.

D. Livermore, E. Fagan, D. James, 2006, The Journal of antimicrobial chemotherapy.

Zone breakpoints, by the CLSI disc method, for 15 μg tigecycline discs corresponding to EUCAST MIC breakpoints.

D. Livermore, D. James, M. Warner, 2008, The Journal of antimicrobial chemotherapy.

Disruption of vanS by IS1216V in a Clinical Isolate of Enterococcus faecium with VanA Glycopeptide Resistance

N. Woodford, D. James, A. L. Da Costa Darini, 1999, Antimicrobial Agents and Chemotherapy.

Rapid enumeration of viable Legionella pneumophila serogroup 1

D. James, G. Vesey, J. Colbourne, 1990 .

Fusidic-acid use and resistance

D. Livermore, G. Duckworth, D. James, 2002, The Lancet.